Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Guardant Health (GH) PT Lowered to $130 at Stifel
February 24, 2022 6:57 AM ESTStifel analyst Daniel Arias lowered the price target on Guardant Health (NASDAQ: GH) to $130.00 (from $160.00) while maintaining a Buy rating.
The analyst commented, "GH finished the year with a good beat and an initial 2022 outlook that includes solid clinical volume growth expectations... More
Guardant Health (GH) PT Lowered to $110 at Cowen
February 24, 2022 6:42 AM ESTCowen analyst Max Masucci lowered the price target on Guardant Health (NASDAQ: GH) to $110.00 (from $170.00) while maintaining an Outperform rating.
The analyst commented, "With the ECLIPSE trial readout expected in mid-2022, GH is approaching another landmark event for the field of cancer... More
Guardant Health (GH) Tops Q4 EPS by 46c
February 23, 2022 4:15 PM ESTGuardant Health (NASDAQ: GH) reported Q4 EPS of ($0.69), $0.46 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $108 million versus the consensus estimate of $98.61 million.
GUIDANCE:
Guardant Health sees FY2022 revenue of $460-470 million, versus the consensus of... More
